Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

被引：0
|
作者：
Yoo, Changhoon
Kim, Kyu-Pyo
Song, Ki Byung
Lee, Sang Soo
Park, Do Hyun
Song, Tae Jun
Lee, Seung Soo
Park, Jin-Hong
Hwang, Dae Wook
Lee, Jae Hoon
Shin, Sang Hyun
Shin, Eunseon
Ryoo, Baek-Yeol
Kim, Song Cheol
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[4] Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[6] Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.342
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
    Jeong, J. H.
    Yoo, C.
    Kim, K-P.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 263 - 263
  • [2] A phase II trial of preoperative FOLFIRINOX followed by gemcitabine-based chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC).
    Wysota, Michael
    Jirgal, Amanda
    Acuna-Villaorduna, Ana
    Viswanathan, Shankar
    Kaubisch, Andreas
    Gadde, Eswar
    Kabarriti, Rafi
    Goel, Sanjay
    Chuy, Jennifer W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101
    Katz, Matthew H. G.
    Shi, Qian
    Ahmad, Syed A.
    Herman, Joseph M.
    Marsh, Robert de Wilton
    Collisson, Eric Andrew
    Schwartz, Lawrence H.
    Martin, Robert C. G.
    Conway, William Charles
    Truty, Mark
    Kindler, Hedy Lee
    Lowy, Andrew M.
    Philip, Philip Agop
    Bekaii-Saab, Tanios S.
    Cardin, Dana Backlund
    LoConte, Noelle K.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
    Acuna-Villaorduna, Ana
    Shankar, Viswanathan
    Wysota, Michael
    Jirgal, Amanda
    Kabarriti, Rafi
    Bellemare, Sarah
    Goldman, Inessa
    Kaubisch, Andreas
    Aparo, Santiago
    Goel, Sanjay
    Chuy, Jennifer
    CANCER CONTROL, 2022, 29
  • [5] Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
    Changhoon Yoo
    Sang Soo Lee
    Ki Byung Song
    Jae Ho Jeong
    Jaewon Hyung
    Do Hyun Park
    Tae Jun Song
    Dong Wan Seo
    Sung Koo Lee
    Myung-Hwan Kim
    Seung Soo Lee
    Jin Hee Kim
    Hyung-seung Jin
    Jin-hong Park
    Dae Wook Hwang
    Jae Hoon Lee
    Woohyung Lee
    Heung-Moon Chang
    Kyu-pyo Kim
    Baek-Yeol Ryoo
    Song Cheol Kim
    British Journal of Cancer, 2020, 123 : 362 - 368
  • [6] Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
    Yoo, Changhoon
    Lee, Sang Soo
    Song, Ki Byung
    Jeong, Jae Ho
    Hyung, Jaewon
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Lee, Seung Soo
    Kim, Jin Hee
    Jin, Hyung-seung
    Park, Jin-hong
    Hwang, Dae Wook
    Lee, Jae Hoon
    Lee, Woohyung
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Ryoo, Baek-Yeol
    Kim, Song Cheol
    BRITISH JOURNAL OF CANCER, 2020, 123 (03) : 362 - 368
  • [7] Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.
    Shahda, Safi
    House, Michael Garrett
    Zyromski, Nicholas J.
    Sehdev, Amikar
    Cramer, Harvey M.
    Flynn, Janet
    Akisik, Fatih
    Ceppa, Eugene P.
    Schmidt, C. Max
    Nakeeb, Attila
    Lin, Jingmei
    Perkins, Susan M.
    Burney, Heather
    O'Neil, Bert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
    Lambert, A.
    Bouche, O.
    Ayav, A.
    Bachet, J-B.
    Schwarz, L.
    Piessen, G.
    Vendrely, V.
    Laurent, V.
    Thibaudeau, E.
    Miglianico, L.
    Rinaldi, Y.
    Hammel, P.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2024, 35 : 1252 - 1252
  • [9] Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)
    Conroy, T.
    Hammel, P.
    Turpin, A.
    Belletier, C.
    Wei, A.
    Mitry, E.
    Lopez, A.
    Francois, E.
    Artru, P.
    Biagi, J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Bouche, O.
    Lambert, A.
    Monard, L.
    Rat, P.
    Castan, F.
    Bachet, J. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1334 - S1334
  • [10] A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC)
    Osipov, Arsen
    Sugar, Elizabeth
    Ferguson, Anna
    Durham, Jennifer
    Rodriguez, Christina
    Parkinson, Rose
    Sena, Laura
    Zheng, Lei
    Wolfgang, Christopher
    Burkhart, Richard
    He, Jin
    Weiss, Matthew
    Narang, Amol
    Laheru, Daniel
    Azad, Nilofer
    Jaffee, Elizabeth
    Weekes, Colin
    Yarchoan, Mark
    CANCER RESEARCH, 2019, 79 (13)
12345